Applies to Medicaid plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
Prediabetes with metformin failure/intolerance/contraindication
All of:
- Diagnosis of prediabetes
- Baseline A1C ≥ 5.7% and < 6.5%
Plus any one of:
- Inadequate response to metformin at daily dose of 2000 mg/day
- Adverse reaction to metformin
- Contraindication to metformin at daily dose of 2000 mg/day
Documentation to bring
- Diagnosis of prediabetes
- Baseline A1C lab result (≥ 5.7% and < 6.5%)
- Documentation of inadequate response to metformin at 2000 mg/day, OR adverse reaction to metformin, OR contraindication to metformin at 2000 mg/day
- For continuation: documentation of reduction in A1C or treatment plan to address A1C reduction
Approval and renewal
- Renewal: Improvement in A1C.
- Renewal: Documentation of reduction in A1C or a treatment plan to address reduction in A1C.
Policy note: Prediabetes criteria for Ozempic aligned with Mounjaro, Trulicity, Victoza as of February 17, 2026. Requires diagnosis, baseline A1C, and inadequate response, adverse reaction, or contraindication to metformin at 2000 mg/day. This is listed in the anti-diabetic guideline section. Note: The JSON schema uses 'indication' enum values; prediabetes does not have a dedicated enum value so it is captured under 'diabetes' with notes. The A1C min/A1C max reflect the prediabetes diagnostic range.
source: Fallon Health Plan Medicaid prior authorization policy · View policy document (PDF)